Inactive Instrument

Press Releases ERYTECH Pharma LIQUIDNET SYSTEMS

Equities

PHAXIAM Therapeutics S A : announces the success of its rights issue of €7.8m	06-28	PU
Results of the Combined General Meeting of 28 June 2024	06-28	GL
Results of the Combined General Meeting of 28 June 2024	06-28	AQ
PHAXIAM announces the availability of the preparatory documents for the Combined General Meeting of 28 June 2024	06-07	GL
PHAXIAM provides Business and Financial Update for the First Quarter of 2024	05-15	GL
PHAXIAM Therapeutics announces enrolment of the first patient in the phase 1 study for the treatment of endocarditis infections caused by Staphylococcus aureus	04-15	GL
PHAXIAM Therapeutics announces filing of its 2023 Universal Registration Document (URD)	04-05	GL
PHAXIAM Announces 2023 Full-Year Results and Provides Business Update	03-20	GL
PHAXIAM Therapeutics announces effectiveness of voluntary delisting of American Depositary Shares from Nasdaq Stock Market	03-11	GL
PHAXIAM Therapeutics announces intention to voluntary delist American Depositary Shares from The Nasdaq Capital Market	02-20	GL
PHAXIAM Therapeutics announces intention to voluntary delist American Depositary Shares from The Nasdaq Capital Market	02-20	AQ

No results for this search